Covetrus Stock

Covetrus ROE

Delisted

The Return on Equity (ROE) of Covetrus (CVET) as of Aug 20, 2026 is -3.57 %. In the previous year, Return on Equity (ROE) was -1.24 % — a change of 189.10% (lower).

ROE

-3.57 %

YoY

189.10%

Last updated:

In 2026, Covetrus's return on equity (ROE) was -3.57 %, a 189.10% increase from the -1.24 % ROE in the previous year.

Access this data via the Eulerpool API

Covetrus Stock analysis

What does Covetrus do? Covetrus Inc is a global company specializing in providing services and products for veterinarians, animal clinics, and pet owners. It was formed in 2019 through a merger between the animal health divisions of Henry Schein and Vets First Choice. Covetrus traces its history back to 1856 when Henry Schein was founded as a small wholesale drug company. Over the years, the company expanded into new industries and markets. In the 2000s, Henry Schein began serving the animal health industry and established Vets First Choice in 2010 to offer a wider range of services and products to veterinarians and animal clinics. With the merger of Vets First Choice and Henry Schein's animal health division in 2019, Covetrus was created as a company with a broad spectrum of products and services for the animal health industry. Covetrus is headquartered in Portland, Maine, USA, and operates in over 25 countries. Its business model is based on providing services and products for veterinarians, animal clinics, and pet owners. The company is divided into several business segments, including diagnostics, pharmaceuticals, and consumables. In the diagnostics area, Covetrus offers a wide range of laboratory diagnostic services for veterinarians, including blood tests, imaging, fecal tests, and genetic tests. These test results help veterinarians diagnose and treat diseases in pets. In the pharmaceutical area, Covetrus offers veterinary medicines for various types of pets, including dogs, cats, and horses. These medicines are developed by leading pharmaceutical companies, and Covetrus provides veterinarians with a reliable supply chain for these products. The most recent business segment of Covetrus is the consumables area. Here, the company offers a wide range of products for veterinarians and animal clinics, including medical devices, surgical instruments, consumables for routine examinations, and more. In addition to these three main business segments, Covetrus also offers a variety of services, including practice management systems, training for veterinarians and animal clinics, financial services, and more. These services are designed to help veterinarians and animal clinics optimize their operations and improve their quality. The company has also developed a mobile application called 'Covetrus Connect' which provides veterinarians and animal clinics with an easier way to access products and services, place orders, and manage their operations. Overall, Covetrus is an innovative and rapidly growing company in the animal health industry. With a wide range of products and services tailored to the needs of veterinarians, animal clinics, and pet owners, the company is well-positioned to continue growing in this emerging market. Covetrus is one of the most popular companies on Eulerpool.

ROE Details

Decoding Covetrus's Return on Equity (ROE)

Covetrus's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Covetrus's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Covetrus's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Covetrus’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Covetrus stock

Return on Equity (ROE) of Covetrus is -3.57 % in 2026.

Return on Equity (ROE) of Covetrus changed from -1.24 % to -3.57 %, representing a 189.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Covetrus since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Covetrus with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Covetrus

All Key Metrics — Covetrus